CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in CNS Pharmaceuticals, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −1 vs. Q1 2026
- Shares held
- 280.4K
- +134.8K (+92.6%) vs. Q1 2026
- Total value
- $1.34M
- +$991.8K (+284.4%) vs. Q1 2026
- New holders
- 4
- 2 more added
- Sold out
- 5
- 2 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.1K |
| Q4 2023 | 16 | $425.4K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.7K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $836.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 135,830 | $649.3K | 0.11% | +90,000+196.4% | Added |
| ADAR1 Capital Management, LLC | 70,000 | $334.6K | 0.02% | +70,000 | New |
| Stonepine Capital Management, LLC | 41,573 | $198.7K | 0.15% | −19,427−31.8% | Reduced |
| Boothbay Fund Management, LLC | 13,524 | $64.6K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 10,226 | $48.9K | 0.00% | +10,226 | New |
| Vanguard Capital Management LLC | 6,993 | $33.4K | 0.00% | +6,993 | New |
| UBS Group AG | 1,461 | $6.98K | 0.00% | +732+100.4% | Added |
| Tower Research Capital LLC (TRC) | 799 | $3.82K | 0.00% | −511−39.0% | Reduced |
| Barclays PLC | 19 | $91 | 0.00% | +19 | New |
| Barrett & Company, Inc. | 8 | $38 | 0.00% | 00.0% | Unchanged |
| Danske Bank A/S | 1 | $5 | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −23,189−100.0% | Sold out |
| Sound Income Strategies, LLC | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| MAI Capital Management | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −1−100.0% | Sold out |